Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Vaxcyte (PCVX) Return on Capital Employed (2020 - 2026)

Vaxcyte (PCVX) has 7 years of Return on Capital Employed data on record, last reported at 37.11% in Q1 2026.

  • On a quarterly basis, Return on Capital Employed fell 1812.0% to 37.11% in Q1 2026 year-over-year; TTM through Mar 2026 was 37.11%, a 1812.0% decrease, with the full-year FY2025 number at 30.27%, down 572.0% from a year prior.
  • Return on Capital Employed reached 37.11% in Q1 2026 per PCVX's latest filing, down from 32.06% in the prior quarter.
  • Over the last five years, Return on Capital Employed for PCVX hit a ceiling of 16.77% in Q4 2024 and a floor of 47.12% in Q3 2022.
  • A 5-year average of 29.75% and a median of 28.77% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: soared 2180bps in 2023, then tumbled -1812bps in 2026.
  • Tracing PCVX's Return on Capital Employed over 5 years: stood at 34.74% in 2022, then decreased by -3bps to 35.82% in 2023, then surged by 53bps to 16.77% in 2024, then tumbled by -91bps to 32.06% in 2025, then dropped by -16bps to 37.11% in 2026.
  • Business Quant data shows Return on Capital Employed for PCVX at 37.11% in Q1 2026, 32.06% in Q4 2025, and 26.71% in Q3 2025.